CN102574922A - 抗tgf-beta受体ii型单结构域抗体 - Google Patents
抗tgf-beta受体ii型单结构域抗体 Download PDFInfo
- Publication number
- CN102574922A CN102574922A CN2010800450323A CN201080045032A CN102574922A CN 102574922 A CN102574922 A CN 102574922A CN 2010800450323 A CN2010800450323 A CN 2010800450323A CN 201080045032 A CN201080045032 A CN 201080045032A CN 102574922 A CN102574922 A CN 102574922A
- Authority
- CN
- China
- Prior art keywords
- tgfbetarii
- variable domains
- tegeline
- polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22933409P | 2009-07-29 | 2009-07-29 | |
US61/229334 | 2009-07-29 | ||
PCT/EP2010/060867 WO2011012609A2 (en) | 2009-07-29 | 2010-07-27 | Ligands that bind tgf-beta receptor rii |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102574922A true CN102574922A (zh) | 2012-07-11 |
Family
ID=43067099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800450323A Pending CN102574922A (zh) | 2009-07-29 | 2010-07-27 | 抗tgf-beta受体ii型单结构域抗体 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9109031B2 (ja) |
EP (1) | EP2459593A2 (ja) |
JP (2) | JP2013500030A (ja) |
KR (1) | KR20120063475A (ja) |
CN (1) | CN102574922A (ja) |
AU (1) | AU2010277629B2 (ja) |
BR (1) | BR112012001977A2 (ja) |
CA (1) | CA2768981A1 (ja) |
EA (1) | EA026097B1 (ja) |
IL (1) | IL217458A0 (ja) |
IN (1) | IN2012DN00412A (ja) |
MX (1) | MX2012001278A (ja) |
SG (1) | SG178135A1 (ja) |
WO (1) | WO2011012609A2 (ja) |
ZA (1) | ZA201200372B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883181A (zh) * | 2016-04-05 | 2018-11-23 | 葛兰素史密斯克莱知识产权发展有限公司 | 在免疫疗法中抑制TGFβ |
CN109328196A (zh) * | 2016-05-09 | 2019-02-12 | 奥斯陆大学医院Hf | 识别TGFβRII的移码突变体的T细胞受体 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG191762A1 (en) | 2011-01-06 | 2013-08-30 | Glaxo Group Ltd | Ligands that bind tgf-beta receptor ii |
US20200331984A1 (en) * | 2016-09-20 | 2020-10-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface |
JP2020526218A (ja) | 2017-07-14 | 2020-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 移植拒絶リスクを予測する新規の方法 |
EP3762429A4 (en) | 2018-03-09 | 2022-03-23 | University of Pittsburgh - Of the Commonwealth System of Higher Education | DELIVERY OF BIOLOGICAL AGENTS TO TISSUE |
GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
CA3208365A1 (en) | 2021-02-15 | 2022-08-18 | Chantal KUHN | Cell therapy compositions and methods for modulating tgf-b signaling |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1245676A1 (en) * | 1999-11-18 | 2002-10-02 | Japan Tobacco Inc. | Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof |
WO2003011908A2 (en) * | 2001-07-31 | 2003-02-13 | Petra Knaus | Mutant forms of the tgf-b type ii receptor which bind all tgf-b isoforms and the use thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
WO2004081026A2 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Polypeptides |
DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
EP2366718A3 (en) | 2002-06-28 | 2012-05-02 | Domantis Limited | Ligand |
JP2004121001A (ja) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | TGF−βII型受容体に対する高親和性モノクローナル抗体 |
JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン.ヴェー. | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
WO2004101790A1 (en) | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
ATE479760T1 (de) | 2004-03-24 | 2010-09-15 | Domantis Ltd | Universelles signalpeptid gas1 |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
CN101578298A (zh) | 2006-01-24 | 2009-11-11 | 杜门蒂斯有限公司 | 结合il-4和/或il-13的配体 |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
-
2010
- 2010-07-27 EP EP10735014A patent/EP2459593A2/en not_active Withdrawn
- 2010-07-27 AU AU2010277629A patent/AU2010277629B2/en not_active Ceased
- 2010-07-27 CN CN2010800450323A patent/CN102574922A/zh active Pending
- 2010-07-27 JP JP2012522147A patent/JP2013500030A/ja active Pending
- 2010-07-27 SG SG2012006029A patent/SG178135A1/en unknown
- 2010-07-27 WO PCT/EP2010/060867 patent/WO2011012609A2/en active Application Filing
- 2010-07-27 BR BR112012001977A patent/BR112012001977A2/pt not_active Application Discontinuation
- 2010-07-27 IN IN412DEN2012 patent/IN2012DN00412A/en unknown
- 2010-07-27 EA EA201290028A patent/EA026097B1/ru not_active IP Right Cessation
- 2010-07-27 MX MX2012001278A patent/MX2012001278A/es not_active Application Discontinuation
- 2010-07-27 US US13/387,376 patent/US9109031B2/en not_active Expired - Fee Related
- 2010-07-27 KR KR1020127005555A patent/KR20120063475A/ko not_active Application Discontinuation
- 2010-07-27 CA CA2768981A patent/CA2768981A1/en not_active Abandoned
-
2012
- 2012-01-10 IL IL217458A patent/IL217458A0/en unknown
- 2012-01-17 ZA ZA2012/00372A patent/ZA201200372B/en unknown
-
2015
- 2015-10-09 JP JP2015201067A patent/JP2016053039A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1245676A1 (en) * | 1999-11-18 | 2002-10-02 | Japan Tobacco Inc. | Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof |
WO2003011908A2 (en) * | 2001-07-31 | 2003-02-13 | Petra Knaus | Mutant forms of the tgf-b type ii receptor which bind all tgf-b isoforms and the use thereof |
Non-Patent Citations (2)
Title |
---|
BROWN C B ET AL.,: "Antibodies directed against the chicken type II TGF beta receptor idenify endothelial cells in the developing chicken and quail", 《DEVELOPMENT DYNAMICS:AN OFFICIAL PUBLICATION OF THE AMERICAN ASSOCIATION OF ANATOMISTS》, vol. 215, no. 1, 31 May 1999 (1999-05-31), pages 79 - 85 * |
KASUGA H ET AL.,: "Effects of anti-TGF-beta type II receptor antibody on experimental glomerulonephritis", 《KIDNEY INTERNATIONAL》, vol. 60, no. 5, 30 November 2001 (2001-11-30), pages 1745 - 1755, XP002610380 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883181A (zh) * | 2016-04-05 | 2018-11-23 | 葛兰素史密斯克莱知识产权发展有限公司 | 在免疫疗法中抑制TGFβ |
CN109328196A (zh) * | 2016-05-09 | 2019-02-12 | 奥斯陆大学医院Hf | 识别TGFβRII的移码突变体的T细胞受体 |
CN109328196B (zh) * | 2016-05-09 | 2022-11-01 | 奥斯陆大学医院Hf | 识别TGFβRII的移码突变体的T细胞受体 |
Also Published As
Publication number | Publication date |
---|---|
EA026097B1 (ru) | 2017-03-31 |
JP2013500030A (ja) | 2013-01-07 |
US9109031B2 (en) | 2015-08-18 |
AU2010277629A1 (en) | 2012-02-16 |
CA2768981A1 (en) | 2011-02-03 |
BR112012001977A2 (pt) | 2017-01-31 |
MX2012001278A (es) | 2012-03-16 |
EA201290028A1 (ru) | 2012-08-30 |
SG178135A1 (en) | 2012-03-29 |
KR20120063475A (ko) | 2012-06-15 |
WO2011012609A3 (en) | 2011-09-15 |
IL217458A0 (en) | 2012-02-29 |
US20120129778A1 (en) | 2012-05-24 |
IN2012DN00412A (ja) | 2015-05-22 |
AU2010277629B2 (en) | 2016-05-19 |
WO2011012609A2 (en) | 2011-02-03 |
ZA201200372B (en) | 2013-06-26 |
JP2016053039A (ja) | 2016-04-14 |
EP2459593A2 (en) | 2012-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200079850A1 (en) | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same | |
JP6453289B2 (ja) | Tgf−ベータ受容体iiに結合するリガンド | |
KR102143506B1 (ko) | 변형된 단백질 및 펩티드 | |
JP2023065375A (ja) | 胸腺間質性リンパ球性新生因子に結合することができる抗原結合タンパク質 | |
CN107098971B (zh) | 抗il-17a,il-17f和/或il17-a/f的氨基酸序列以及包含其的多肽 | |
JP5833009B2 (ja) | 抗脈管形成療法のための二重特異性結合分子 | |
US20240026013A2 (en) | Cx3cr1-binding polypeptides comprising immunoglobulin single variable domains | |
CN102574922A (zh) | 抗tgf-beta受体ii型单结构域抗体 | |
CA2977621C (en) | Antibody binding to tfpi and composition comprising the same | |
CN108473561B (zh) | 抑制cd40l的多肽 | |
US20210130483A1 (en) | Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies | |
US10696741B2 (en) | Anti-IL-22R antibodies | |
US20200190192A1 (en) | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same | |
KR20170036505A (ko) | 신규 항-tfpi 항체 및 이를 포함하는 조성물 | |
KR20230087552A (ko) | Cd45를 다량체화하는 결합 분자 | |
NZ612839B2 (en) | Ligands that bind tgf-beta receptor ii | |
OA17072A (en) | CX3CR1-binding polypeptides. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120711 |